Clinical Trials Browser

Phase 1/2 × Ependymoma × 90 days × Clear all

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT06639607 2026-06-03

PRiME II

Phase 1/2 Not yet recruiting

68 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT06161519 2026-05-13

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Phase 1/2 Recruiting

146 enrolled

CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Recurrence

NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Phase 1/2 Not yet recruiting

120 enrolled

CNS

Ependymoma, Glioma, Neoplasms, Recurrence

NCT05278208 2026-04-13

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Phase 1/2 Recruiting

65 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Germ Cell and Embryonal, Central Nervous System Neoplasms

Clinical Trials

LUPARPED

PRiME II

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors